| Description: The 4H11 monoclonal antibody reacts with human CD34, also known as mucosialin. CD34 belongs to a protein family which also includes endoglycan and podocalyxin. Members of this family are single pass transmembrane proteins with a heavily glycosylated extracellular and N-terminal mucin domain. CD34 was first identified as an antigen expressed on hematopoietic progenitors, and has since been extensively used as a marker to isolate cells capable of hematopoietic cell engraftment. In spite of this, the function of CD34 remains unresolved. In addition to expression on hematopoietic progenitors, CD34 is expressed on some populations of mesenchymal stem cells, tumor cell lines, and by vascular endothelia in the adult. Epitopes of CD34 have been assigned to three classes (class I, II or III) based on their differential sensitivity to enzymatic cleavage by neuraminidase, chymopapain, or O-glycoprotease. According to this analysis, the 4H11 antibody belongs to class III, indicating that it reacts with a protein epitope.Applications Reported: This 4H11 antibody has been reported for use in flow cytometric analysis.Applications Tested: This 4H11 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.125 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.Light sensitivity: This tandem dye is sensitive photo-induced oxidation. Please protect this vial and stained samples from light.Fixation: Samples can be stored in IC Fixation Buffer (cat. 00-8222) (100 µL cell sample + 100 µL IC Fixation Buffer) or 1-step Fix/Lyse Solution (cat. 00-5333) for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation. Some generalizations regarding fluorophore performance after fixation can be made, but clone specific performance should be determined empirically.Excitation: 488-561 nm; Emission: 775 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser.Filtration: 0.2 µm post-manufacturing filtered. |
| 1.Genome biologySingle-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways."25-0349 was used in Flow cytometry/Cell sorting to clarify the cellular hierarchy in human megakaryocyte/erythroid lineage commitment and highlight the importance of using a combination of single-cell approaches to dissect cellular heterogeneity."Authors Psaila B,Barkas N,Iskander D,Roy A,Anderson S,Ashley N,Caputo VS,Lichtenberg J,Loaiza S,Bodine DM,Karadimitris A,Mead AJ,Roberts I2.Nature communicationsSF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment."25-0349 was used in Flow cytometry/Cell sorting to demonstrate that mutations to SF3B1 can arise from CD34(+)CD38(-)CD45RA(-)CD90(+)CD49f(+) haematopoietic stem cells and is an initiating event in myelodysplastic syndrome patients."Authors Mian SA,Rouault-Pierre K,Smith AE,Seidl T,Pizzitola I,Kizilors A,Kulasekararaj AG,Bonnet D,Mufti GJ3.NatureReprogramming human endothelial cells to haematopoietic cells requires vascular induction."25-0349 was used in Flow cytometry/Cell sorting to investigate the role of inductive cues from the vascular niche in coordinating and sustaining haematopoietic specification."Authors Sandler VM,Lis R,Liu Y,Kedem A,James D,Elemento O,Butler JM,Scandura JM,Rafii S4.Human molecular geneticsDevelopmental transcriptome analysis of human erythropoiesis."25-0349 was used in Flow cytometry/Cell sorting to perform RNA-seq on CD34(+) cells after ex vivo differentiation from the earliest into the most mature erythroid cell stages."Authors Shi L,Lin YH,Sierant MC,Zhu F,Cui S,Guan Y,Sartor MA,Tanabe O,Lim KC,Engel JD5.BloodJAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo."25-0349 was used in Flow cytometry/Cell sorting to investigate how JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo."Authors Gallipoli P,Cook A,Rhodes S,Hopcroft L,Wheadon H,Whetton AD,Jørgensen HG,Bhatia R,Holyoake TL |
QQ:1749072012